Table 2 Univariate analysis of clinicopathological characteristics
Characteristics (n = 6599) | Number of cases (%) | Number of ALNM (%) | p valuea |
|---|---|---|---|
NG (Nuclear grade) | <0.0001 | ||
1 | 497 (7.5%) | 122 (24.5%) | |
2 | 3551 (53.8%) | 1104 (31.1%) | |
3 | 2551 (38.7%) | 902 (35.4%) | |
HG (Histologic grade) | <0.0001 | ||
1 | 1494 (22.6%) | 370 (24.8%) | |
2 | 3248 (49.2%) | 1140 (35.1%) | |
3 | 1857 (28.1%) | 618 (33.3%) | |
HG1 (Tubule formation) | <0.0001 | ||
1 | 473 (7.2%) | 93 (19.7%) | |
2 | 1515 (23.0%) | 456 (30.1%) | |
3 | 4611 (69.9%) | 1579 (34.2%) | |
HG2 (Nuclear pleomorphism) | <0.0001 | ||
1 | 490 (7.4%) | 124 (25.3%) | |
2 | 3569 (54.1%) | 1105 (31.0%) | |
3 | 2540 (38.5%) | 899 (35.4%) | |
HG3 (Mitotic rate) | 0.10 | ||
1 | 4038 (61.2%) | 1263 (31.3%) | |
2 | 1318 (20.0%) | 441 (33.5%) | |
3 | 1243 (18.8%) | 424 (34.1%) | |
DCIS/LCIS | <0.0001 | ||
no DCIS/LCIS | 3339 (50.6%) | 1148 (34.4%) | |
DCIS/LCIS present, EIC(−) | 1806 (27.4%) | 623 (34.5%) | |
DCIS/LCIS present, EIC(+) | 1454 (22.0%) | 357 (24.6%) | |
ER status | 0.0004 | ||
Negative | 1559 (23.6%) | 445 (28.5%) | |
Positive | 5040 (76.4%) | 1683 (33.4%) | |
PR status | 0.0057 | ||
Negative | 2529 (38.3%) | 764 (30.2%) | |
Positive | 4070 (61.7%) | 1364 (33.5%) | |
HER2 status | 0.026 | ||
Negative | 5264 (79.8%) | 1663 (31.6%) | |
Positive | 1335 (20.2%) | 465 (34.8%) | |
Tumor location | 0.23 | ||
Right | 3174 (48.1%) | 1056 (33.3%) | |
Left | 3318 (50.3%) | 1038 (31.3%) | |
Both | 107 (1.6%) | 34 (31.8%) | |
Tumor size (mm) | <0.0001 | ||
0–1 | 58 (0.9%) | 4 (6.9%) | |
1–5 | 351 (5.3%) | 53 (15.1%) | |
5–10 | 1019 (15.4%) | 161 (15.8%) | |
10–20 | 2903 (44.0%) | 820 (28.2%) | |
20–50 | 2118 (32.1%) | 975 (46.0%) | |
50–170 | 150 (2.3%) | 115 (76.7%) | |
Ki-67 LI (%) | 0.15 | ||
0–20 | 3517 (53.3%) | 1137 (32.3%) | |
20–40 | 1339 (20.3%) | 458 (34.2%) | |
40–60 | 626 (9.5%) | 195 (31.2%) | |
60–80 | 355 (5.4%) | 101 (28.5%) | |
80–100 | 174 (2.6%) | 48 (27.6%) | |
Not applicable | 588 (8.9%) | - |
